Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Repurchased
Ratios

Ligand Pharmaceuticals (LGND) Other Gross PP&E Adjustments (2016 - 2025)

Ligand Pharmaceuticals' Other Gross PP&E Adjustments history spans 15 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments fell 80.98% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, down 80.98%, while the annual FY2025 figure was $3.0 million, 80.98% down from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was $3.0 million at Ligand Pharmaceuticals, up from -$7.6 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $24.0 million in Q4 2021 and bottomed at -$32.1 million in Q3 2022.
  • The 5-year median for Other Gross PP&E Adjustments is -$7.3 million (2024), against an average of -$4.1 million.
  • The largest YoY upside for Other Gross PP&E Adjustments was 759.92% in 2021 against a maximum downside of 203.37% in 2021.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $24.0 million in 2021, then fell by 25.12% to $17.9 million in 2022, then dropped by 8.19% to $16.5 million in 2023, then fell by 4.24% to $15.8 million in 2024, then tumbled by 80.98% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Other Gross PP&E Adjustments are $3.0 million (Q4 2025), -$7.6 million (Q3 2025), and -$8.0 million (Q2 2025).